Extra Gene Makes Mice Manic

A common mood-stabilizing drug, valproate, is found to control manic-like behavior induced in mice with an extra copy of a gene called SHANK3

Join Our Community of Science Lovers!

Duplication of a single gene — and too much of the corresponding protein in brain cells — causes mice to have seizures and display manic-like behavior, a study has found. But a widely used drug reversed the symptoms, suggesting that it could also help some people with hyperactivity who do not respond to common treatments.

Smooth functioning at the synapses, the junctions between brain cells, is crucial to functions that control everything from social etiquette to everyday decision-making. It is increasingly thought that some neuropsychiatric disorders are caused by function of the synapses going awry, and indeed researchers have found that neuropsychiatric conditions such as schizophrenia and autism can sometimes be traced to missing or mutated copies of SHANK3, a gene that encodes one of the 'architectural' proteins that help to ensure that messages are relayed properly between cells. Some people with attention deficit hyperactivity disorder (ADHD), Asperger's syndrome or schizophrenia have an extra copy of a wider region of DNA that contains SHANK3.

To explore the role of SHANK3, Huda Zoghbi, a neurogeneticist at Baylor College of Medicine in Houston, Texas, and her colleagues created mice with duplicate copies of the gene. “The mouse was remarkably hyperactive, running around like mad,” says Zoghbi. But the animals did not respond to stimulant medications typically used to treat ADHD. Instead, their hyperactivity grew much worse. “That’s when we knew this was not typical ADHD,” says Zoghbi. The study is published today in Nature.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


The paper is a “really good example of the importance of gene dosage”, says Thomas Insel, director of the US National Institute of Mental Health in Bethesda, Maryland. “It matters a lot whether you have no copies, one copy, two copies” or more of a given gene, he says.

Human parallels
In addition to hyperactivity, the mice displayed a combination of mania-like behaviors and seizures, which are indicative of a disorder called hyperkinesia. When the researchers sifted through clinical databases, they found records of two people whose psychiatric profiles resembled those of the mice, and who also carried a duplication of SHANK3. One had bipolar disorder and epilepsy; the other had seizures and ADHD characterized by hyperactivity, poor attention and compulsive behavior. Like the mice, this person had not responded well to amphetamines used to treat ADHD.

After trying various treatments, the researchers gave the mice valproate, an anticonvulsant and mood-stabilizing drug commonly used to treat bipolar disorder and epilepsy. Remarkably, the drug reversed the psychiatric effects. The results suggest that excess SHANK3 protein drives a psychiatric syndrome that can be treated effectively.

Joe Gleeson, a pediatric neurologist and geneticist at the University of California, San Diego, says that the study is “one of the first to explore, in a comprehensive way” the importance of gene dosage in mouse neurological disorders. He says that the paper addresses the underpinnings of these disorders on all fronts, from psychopharmacology to proteomics and human genomics, and notes that “the results are all in alignment”.

This article is reproduced with permission from the magazine Nature. The article was first published on October 23, 2013.

First published in 1869, Nature is the world's leading multidisciplinary science journal. Nature publishes the finest peer-reviewed research that drives ground-breaking discovery, and is read by thought-leaders and decision-makers around the world.

More by Nature magazine

It’s Time to Stand Up for Science

If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.

I’ve been a Scientific American subscriber since I was 12 years old, and it helped shape the way I look at the world. SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.

If you subscribe to Scientific American, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.

In return, you get essential news, captivating podcasts, brilliant infographics, can't-miss newsletters, must-watch videos, challenging games, and the science world's best writing and reporting. You can even gift someone a subscription.

There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission.

Thank you,

David M. Ewalt, Editor in Chief, Scientific American

Subscribe